Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Randomized, Double-blind, and Placebo-controlled Multicenter Split Body Trial of Repeated Doses of ACOU085 for the Prevention of Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Next Previous
Trial Profile

Phase IIa Randomized, Double-blind, and Placebo-controlled Multicenter Split Body Trial of Repeated Doses of ACOU085 for the Prevention of Hearing Loss in Testicular Cancer Patients Receiving Cisplatin

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACOU 085 (Primary)
  • Indications Chemotherapy-induced damage; Sensorineural hearing loss
  • Focus Therapeutic Use
  • Acronyms Acousia Study 02; PROHEAR
  • Sponsors Acousia Therapeutics

Most Recent Events

  • 08 Jan 2026 According to an Acousia Therapeutics media release, company is looking forward to review the full unblinded dataset in Q2-Q3 2026
  • 08 Jan 2026 Status changed from recruiting to active, no longer recruiting.
  • 29 Apr 2025 According to an Acousia Therapeutics media release, the trial has successfully enrolled 50 per cent of enrolment in this trial. The trial is being conducted at 13 leading German ENT university clinics and is still actively recruiting. The study is on track to complete enrollment by the end of the second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top